Beta-adrenergic agonists

Giovanni Barisione, Michele Baroffio, Emanuele Crimi, Vito Brusasco

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Inhaled β2-adrenoceptor (β2-AR) agonists are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. In this article, we first review the basic mechanisms by which the β2-adrenergic system contributes to the control of airway smooth muscle tone. Then, we go on describing the structural characteristics of β2-AR and the molecular basis of G-protein-coupled receptor signaling and mechanisms of its desensitization/ dysfunction. In particular, phosphorylation mediated by protein kinase A and β-adrenergic receptor kinase are examined in detail. Finally, we discuss the pivotal role of inhaled β2-AR agonists in the treatment of asthma and the concerns about their safety that have been recently raised.

Original languageEnglish
Pages (from-to)1016-1044
Number of pages29
JournalPharmaceuticals
Volume3
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Adrenergic beta-Agonists
Adrenergic Receptors
Asthma
Essential Drugs
Airway Management
Bronchodilator Agents
G-Protein-Coupled Receptors
Cyclic AMP-Dependent Protein Kinases
Adrenergic Agents
Smooth Muscle
Adrenal Cortex Hormones
Phosphotransferases
Phosphorylation
Safety
Therapeutics

Keywords

  • β-adrenoceptors
  • Airway smooth muscle
  • Bronchodilation
  • Desensitization
  • G-protein-coupled receptor signaling
  • Safety issues

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Barisione, G., Baroffio, M., Crimi, E., & Brusasco, V. (2010). Beta-adrenergic agonists. Pharmaceuticals, 3(4), 1016-1044. https://doi.org/10.3390/ph3041016

Beta-adrenergic agonists. / Barisione, Giovanni; Baroffio, Michele; Crimi, Emanuele; Brusasco, Vito.

In: Pharmaceuticals, Vol. 3, No. 4, 2010, p. 1016-1044.

Research output: Contribution to journalArticle

Barisione, G, Baroffio, M, Crimi, E & Brusasco, V 2010, 'Beta-adrenergic agonists', Pharmaceuticals, vol. 3, no. 4, pp. 1016-1044. https://doi.org/10.3390/ph3041016
Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-adrenergic agonists. Pharmaceuticals. 2010;3(4):1016-1044. https://doi.org/10.3390/ph3041016
Barisione, Giovanni ; Baroffio, Michele ; Crimi, Emanuele ; Brusasco, Vito. / Beta-adrenergic agonists. In: Pharmaceuticals. 2010 ; Vol. 3, No. 4. pp. 1016-1044.
@article{f2471a9916fd460986f3677ebfbe34b2,
title = "Beta-adrenergic agonists",
abstract = "Inhaled β2-adrenoceptor (β2-AR) agonists are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. In this article, we first review the basic mechanisms by which the β2-adrenergic system contributes to the control of airway smooth muscle tone. Then, we go on describing the structural characteristics of β2-AR and the molecular basis of G-protein-coupled receptor signaling and mechanisms of its desensitization/ dysfunction. In particular, phosphorylation mediated by protein kinase A and β-adrenergic receptor kinase are examined in detail. Finally, we discuss the pivotal role of inhaled β2-AR agonists in the treatment of asthma and the concerns about their safety that have been recently raised.",
keywords = "β-adrenoceptors, Airway smooth muscle, Bronchodilation, Desensitization, G-protein-coupled receptor signaling, Safety issues",
author = "Giovanni Barisione and Michele Baroffio and Emanuele Crimi and Vito Brusasco",
year = "2010",
doi = "10.3390/ph3041016",
language = "English",
volume = "3",
pages = "1016--1044",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Beta-adrenergic agonists

AU - Barisione, Giovanni

AU - Baroffio, Michele

AU - Crimi, Emanuele

AU - Brusasco, Vito

PY - 2010

Y1 - 2010

N2 - Inhaled β2-adrenoceptor (β2-AR) agonists are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. In this article, we first review the basic mechanisms by which the β2-adrenergic system contributes to the control of airway smooth muscle tone. Then, we go on describing the structural characteristics of β2-AR and the molecular basis of G-protein-coupled receptor signaling and mechanisms of its desensitization/ dysfunction. In particular, phosphorylation mediated by protein kinase A and β-adrenergic receptor kinase are examined in detail. Finally, we discuss the pivotal role of inhaled β2-AR agonists in the treatment of asthma and the concerns about their safety that have been recently raised.

AB - Inhaled β2-adrenoceptor (β2-AR) agonists are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. In this article, we first review the basic mechanisms by which the β2-adrenergic system contributes to the control of airway smooth muscle tone. Then, we go on describing the structural characteristics of β2-AR and the molecular basis of G-protein-coupled receptor signaling and mechanisms of its desensitization/ dysfunction. In particular, phosphorylation mediated by protein kinase A and β-adrenergic receptor kinase are examined in detail. Finally, we discuss the pivotal role of inhaled β2-AR agonists in the treatment of asthma and the concerns about their safety that have been recently raised.

KW - β-adrenoceptors

KW - Airway smooth muscle

KW - Bronchodilation

KW - Desensitization

KW - G-protein-coupled receptor signaling

KW - Safety issues

UR - http://www.scopus.com/inward/record.url?scp=77952156765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952156765&partnerID=8YFLogxK

U2 - 10.3390/ph3041016

DO - 10.3390/ph3041016

M3 - Article

VL - 3

SP - 1016

EP - 1044

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 4

ER -